Kymanox
Kymanox, a leading consultancy firm headquartered in the United States, has been at the forefront of the life sciences industry since its inception in 2010. With a strong presence across major operational regions, including North America and Europe, Kymanox specialises in providing comprehensive solutions in project management, regulatory affairs, and quality assurance for pharmaceutical and biotechnology companies. The company is renowned for its unique approach to integrating scientific expertise with strategic insights, ensuring clients navigate complex regulatory landscapes effectively. Kymanox has achieved significant milestones, including successful collaborations with top-tier organisations, solidifying its position as a trusted partner in the life sciences sector. With a commitment to innovation and excellence, Kymanox continues to set industry standards, making it a pivotal player in enhancing the efficiency and compliance of drug development processes.
DitchCarbon Score
How does Kymanox's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kymanox's score of 6 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kymanox's reported carbon emissions
Kymanox Corporation, headquartered in the United States, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, Kymanox has established a target to reduce its Scope 1 and Scope 2 emissions by 42% by the year 2030, using 2022 as the baseline year. This target has been validated through the Science Based Targets initiative (SBTi), ensuring alignment with the global goal of limiting temperature rise to 1.5°C. In addition to its focus on direct emissions (Scope 1 and 2), Kymanox is also committed to measuring and reducing its Scope 3 emissions, which encompass indirect emissions from the value chain. This comprehensive approach reflects Kymanox's dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. As a small to medium-sized enterprise, Kymanox's targets are particularly noteworthy, as they demonstrate a proactive stance in addressing climate change and contributing to a more sustainable future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kymanox is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
